Physician profile
Lingpin Hung
NPI 1821250036
$6,489.86
in general payments reported to CMS, 2019-2025
24 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $662 · 2021: $1,118 · 2022: $1,283 · 2023: $860 · 2024: $826 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,677 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,676.64 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,223.34 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $927.29 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amarin Pharma, INC. | $715.80 | 2019-2023 | |
| Lilly USA, LLC | $578.20 | 2019-2025 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $523.60 | 2019-2025 | |
| Abbvie INC. | $520.75 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $321.67 | 2020-2022 | |
| Amgen INC. | $276.19 | 2019-2023 | Evenity, Prolia |
| Radius Health, INC. | $273.16 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.12 | 2021-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $167.17 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $147.90 | 2019-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $145.50 | 2025 | Voquezna |
| Astellas Pharma US INC | $118.49 | 2022-2023 | Myrbetriq, Veozah |
| Ironwood Pharmaceuticals, INC | $70.19 | 2023 | Linzess |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $65.01 | 2023-2024 | Tirosint, Licart, Tirosint |
| Allergan, INC. | $52.82 | 2019 | |
| Glaxosmithkline, LLC. | $42.86 | 2025 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $34.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.14 | 2024 | |
| Ardelyx, INC. | $20.92 | 2025 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $18.91 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.38 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lingpin Hung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.